You are viewing the site in preview mode

Skip to main content

Table 4 Drug resistance mutations present in each EQA panel

From: The Brazilian Network for HIV-1 Genotyping External Quality Control Assurance Programme

  VL1 VL2
  PROTEASE REVERSE TRANSCRIPTASE PROTEASE REVERSE TRANSCRIPTASE
EQA1 WT WT L10V, M36M/I WT
EQA2 V77I M184V, T215Y, K103N, A98G, P225H I54V, L63P, A71V, V82A, L90M WT
EQA3 L10F, K20R, L33F, I54L, V82A Y181C, R211K, T215C L10V, L63P, V77I M41L, M184V, Y188L, L210W, T215Y
EQA4 L10F, L63P, V77I, I84V, I93L D67N, K70R, M184V, T215T/I, K219E K20T, M46I, L63P, A71T, N88G M41L, K103N, V118I, M184V, T215Y
EQA5 E35D, I62V, V71T, I84I, L90L/M K103N, M184M, R221K, L214F, T215L E35D, I62V, A71T, I84I, L90L/M K103N, M184M, R211K, L214F, T215L
  1. (VL1 = viral load 1 of 2000 copies/mL and VL2 = 10,000 copies/mL. WT = wild type virus. A total of five codons at the protease and five codons at reverse transcriptase were selected for analysis. In the absence of drug resistance mutations, randomly selected wild type codons were chosen for the correct interpretation of mutations analysis. In case of ambiguities - mixed viruses population, i.e, M36M/I - we scored as correct only labs that reported the presence of both amino acids.)
Back to article page

Journal of the International AIDS Society

ISSN: 1758-2652